www.fdanews.com/articles/198945-nice-rejects-celgenes-revlimid-for-multiple-myeloma
NICE Rejects Celgene’s Revlimid for Multiple Myeloma
September 10, 2020
The UK’s National Institute of Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) not offer Celgene’s Revlimid (lenalidomide) as a maintenance treatment after an autologous stem-cell transplant for newly diagnosed multiple myeloma in adults.
The institute said it was hard to assess the drug’s benefit relative to its cost because the cost-effectiveness model may not reflect how the product would actually be used by the NHS.
NICE acknowledged that clinical trial results showed Revlimid increased how long patients lived and extended the time before multiple myeloma progressed.